HopeStage
Back to all studies
CompletedNCT00218231

Bupropion compared with placebo for smoking behavior in schizophrenia

About this titleRead the official source — NCT00218231
Medication studyAges 18–80United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 80 years.

Listed locations
Providence and 1 more locationSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJanuary 2004
Recruitment status
Completed
Enrollment listed in the registry
48
Sponsor
National Institute on Drug Abuse (NIDA)
Sponsor type
Research institute
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 80 Years
Official registry ID
NCT00218231
Official title
Show the full official title

Transdermal Nicotine and Bupropion-SR in Schizophrenics (Study 2)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Providence

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is National Institute on Drug Abuse (NIDA), a research institute.

Did this study involve medication?

Yes. The study involved medication, including 300 mg/day bupropion-sr and 0 mg/day bupropion-sr.

Who was this study for?

Listed age limits: 18 years to 80 years.

Want to explore more studies?

Explore studies